|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Hydroxychloroquine and Azithromycin as Treatments for COVID-19
This item is licensed under:Creative Commons Attribution 4.0 International
| Title: | Hydroxychloroquine and Azithromycin as Treatments for COVID-19 |
| Authors: | Ohe, Masashi Browse this author | | Furuya, Ken Browse this author | | Goudarzi, Houman Browse this author →KAKEN DB |
| Keywords: | COVID-19 | | SARS-CoV-2 | | Hydroxychloroquine | | Macrolide | | Azithromycin |
| Issue Date: | 19-May-2020 |
| Publisher: | Gazi University |
| Journal Title: | Gazi Medical Journal |
| Volume: | 31 |
| Issue: | 2A |
| Start Page: | 337 |
| End Page: | 338 |
| Publisher DOI: | 10.12996/gmj.2020.82 |
| Abstract: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak that originated in late 2019 and continues to spread as of 2020 is taking a severe toll on human health and has been acknowledged as a worldwide pandemic. There have been no readily available vaccines or drugs that have been approved to combat the disease (COVID-19) as of yet. Chloroquine (CQ), a drug well-known for its effectiveness in treating malarial and autoimmune disease such as rheumatoid arthritis and lupus erythematosus, has exhibited a promising inhibitory effect for SARS-CoV-2. Hydroxychloroquine (HCQ), a more tolerable derivative of CQ, has also been shown to display potent activity against SARS-CoV-2. Macrolides (MACs) such as erythromycin, clarithromycin, and azithromycin (AZM) not only have the potential for anti-bacterial activity but also have immunomodulatory effects. Lately, the anti-viral effects of MACs have attracted considerable attention. Very recently, HCQ in combination with AZM treatment was reported to be effective for mild form of COVID-19. Because mild form of COVID-19 may take a turn for the worse, resulting in acute respiratory distress syndrome, or mild COVID-19 patients may infect surrounding people with COVID-19, patients should be treated with HCQ in combination with AZM. |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/79157 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
